Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.

IF 4 3区医学 Q1 OBSTETRICS & GYNECOLOGY

Breast Cancer Pub Date : 2025-01-14 DOI:10.1007/s12282-025-01666-x

Erina Iwabuchi, Yasuhiro Miki, Junyao Xu, Ayako Kanai, Takanori Ishida, Takashi Suzuki

{"title":"Tetraspanins CD63 and CD81 as potential prognostic biomarkers in breast cancer.","authors":"Erina Iwabuchi, Yasuhiro Miki, Junyao Xu, Ayako Kanai, Takanori Ishida, Takashi Suzuki","doi":"10.1007/s12282-025-01666-x","DOIUrl":null,"url":null,"abstract":"<p><p>Exosome markers, CD63 and CD81, belong to the tetraspanin family and are expressed in solid tumors. It has been reported that these tetraspanin family members are prognostic factors in some cancers. However, the expression of CD63 and CD81 in pathological breast cancer specimens has not been reported. It has been reported that CD63 promotes the proliferation of breast cancer cells in vitro through yes-associated protein (YAP). Therefore, in this study, the expression of tetraspanin family members, particularly CD63, CD81, and YAP were investigated in breast cancer tissue, by immunohistochemistry, to clarify the relationship between clinicopathological factors and prognosis. The number of CD63 and YAP double-positive breast cancer cells was significantly higher in patients with pathological T factor (pT) status (p = 0.030) and tended to be higher in patients with pathological N factor (pN) status (p = 0.054). Furthermore, the number of CD81 and YAP double-positive breast cancer cells was significantly higher in patients with histological grade (p = 0.015), pT status (p = 0.001), and Ki67 expression (p = 0.049), and tended to be higher in patients with pN status (p = 0.062) and TNM stage (p = 0.052). In addition, CD63 and YAP double-positive breast cancers and CD81 and YAP double-positive breast cancers were associated with shorter disease-free and breast cancer-specific survival, respectively. In conclusion, CD63 and YAP, and CD81 and YAP may serve as potential prognostic biomarkers in patients with breast cancer.</p>","PeriodicalId":56083,"journal":{"name":"Breast Cancer","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12282-025-01666-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Exosome markers, CD63 and CD81, belong to the tetraspanin family and are expressed in solid tumors. It has been reported that these tetraspanin family members are prognostic factors in some cancers. However, the expression of CD63 and CD81 in pathological breast cancer specimens has not been reported. It has been reported that CD63 promotes the proliferation of breast cancer cells in vitro through yes-associated protein (YAP). Therefore, in this study, the expression of tetraspanin family members, particularly CD63, CD81, and YAP were investigated in breast cancer tissue, by immunohistochemistry, to clarify the relationship between clinicopathological factors and prognosis. The number of CD63 and YAP double-positive breast cancer cells was significantly higher in patients with pathological T factor (pT) status (p = 0.030) and tended to be higher in patients with pathological N factor (pN) status (p = 0.054). Furthermore, the number of CD81 and YAP double-positive breast cancer cells was significantly higher in patients with histological grade (p = 0.015), pT status (p = 0.001), and Ki67 expression (p = 0.049), and tended to be higher in patients with pN status (p = 0.062) and TNM stage (p = 0.052). In addition, CD63 and YAP double-positive breast cancers and CD81 and YAP double-positive breast cancers were associated with shorter disease-free and breast cancer-specific survival, respectively. In conclusion, CD63 and YAP, and CD81 and YAP may serve as potential prognostic biomarkers in patients with breast cancer.

查看原文本刊更多论文

四跨蛋白CD63和CD81作为乳腺癌潜在的预后生物标志物。

外泌体标志物CD63和CD81属于四蛋白家族，在实体肿瘤中表达。据报道，这些四蛋白家族成员是某些癌症的预后因素。然而，CD63和CD81在病理乳腺癌标本中的表达尚未见报道。有报道称，CD63在体外通过yes-associated protein （YAP）促进乳腺癌细胞的增殖。因此，本研究采用免疫组化的方法，研究四跨蛋白家族成员，特别是CD63、CD81和YAP在乳腺癌组织中的表达，以阐明临床病理因素与预后的关系。病理T因子（pT）状态患者CD63和YAP双阳性乳腺癌细胞数量显著高于病理N因子（pN）状态患者（p = 0.054），病理T因子（pT）状态患者CD63和YAP双阳性乳腺癌细胞数量显著高于病理T因子（p = 0.030）。CD81和YAP双阳性乳腺癌细胞的数量在组织学分级（p = 0.015）、pT状态（p = 0.001）和Ki67表达（p = 0.049）的患者中显著增加，在pN状态（p = 0.062）和TNM阶段（p = 0.052）的患者中有更高的趋势。此外，CD63和YAP双阳性乳腺癌和CD81和YAP双阳性乳腺癌分别与较短的无病生存期和乳腺癌特异性生存期相关。综上所述，CD63和YAP以及CD81和YAP可能是乳腺癌患者预后的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer ONCOLOGY-OBSTETRICS & GYNECOLOGY

CiteScore

6.70

自引率

2.50%

发文量

105

审稿时长

6-12 weeks

期刊介绍： Breast Cancer, the official journal of the Japanese Breast Cancer Society, publishes articles that contribute to progress in the field, in basic or translational research and also in clinical research, seeking to develop a new focus and new perspectives for all who are concerned with breast cancer. The journal welcomes all original articles describing clinical and epidemiological studies and laboratory investigations regarding breast cancer and related diseases. The journal will consider five types of articles: editorials, review articles, original articles, case reports, and rapid communications. Although editorials and review articles will principally be solicited by the editors, they can also be submitted for peer review, as in the case of original articles. The journal provides the best of up-to-date information on breast cancer, presenting readers with high-impact, original work focusing on pivotal issues.